Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.27
-1.2%
$0.27
$0.20
$1.48
$71.83M2.181.37 million shs271,686 shs
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$2.52
+1.4%
$1.90
$1.11
$5.00
$669.34M1.811.78 million shs775,154 shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.61
-5.0%
$1.57
$1.13
$2.66
$143.23M2.57427,918 shs195,193 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.50
-6.8%
$4.83
$3.61
$11.09
$49.91M1.43362,304 shs142,685 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.30
$0.13
$0.01
$6.17
$541K0.966,759 shs2 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-0.54%+9.28%-1.08%+23.39%-76.95%
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
+0.40%+4.64%+6.44%+82.35%-36.90%
Compugen Ltd. stock logo
CGEN
Compugen
+1.20%-5.06%-5.59%+34.13%-1.74%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+2.11%+10.40%-7.12%+9.77%-50.41%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%+500.00%-70.00%-93.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.429 of 5 stars
3.15.00.00.02.10.80.0
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.1975 of 5 stars
3.51.00.00.00.63.30.6
Compugen Ltd. stock logo
CGEN
Compugen
1.4683 of 5 stars
3.53.00.00.00.60.00.0
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.5883 of 5 stars
3.53.00.04.63.01.71.3
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35398.77% Upside
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32270.58% Upside
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00149.22% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00944.44% Upside
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AUTL, CGEN, TBIO, ADAP, and DTIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/12/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/21/2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
4/11/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.40N/AN/A$0.05 per share5.42
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$10.12M66.14N/AN/A$1.61 per share1.56
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M5.14N/AN/A$0.62 per share2.59
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$68.70M0.73N/AN/A$6.87 per share0.66
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share2.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/8/2025 (Estimated)
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%8/5/2025 (Estimated)

Latest AUTL, CGEN, TBIO, ADAP, and DTIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.2329N/AN/AN/A$12.92 millionN/A
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07N/AN/AN/A$3.95 millionN/A
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million
5/15/2025Q1 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/8/2025Q1 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/A
9.24
9.02
Compugen Ltd. stock logo
CGEN
Compugen
N/A
5.09
5.09
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.45
6.62
6.62
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
330266.14 million197.74 millionOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.09 million10.59 millionNo Data
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable

Recent News About These Companies

Telesis Bio: Q3 Earnings Snapshot
Telesis Bio Announces Departure of Chief Legal Officer
Telesis Bio Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 0.00 (-1.20%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$2.52 +0.04 (+1.41%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Compugen stock logo

Compugen NASDAQ:CGEN

$1.60 -0.09 (-5.03%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$4.50 -0.33 (-6.83%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.30 0.00 (0.00%)
As of 07/10/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.